**Core Concept**
Midostaurin is a multi-targeted tyrosine kinase inhibitor that targets various kinases involved in the pathogenesis of certain hematological malignancies. It is specifically designed to inhibit the FLT3, PDGFRα, and KIT kinases, which play crucial roles in the development and progression of acute myeloid leukemia (AML).

**Why the Correct Answer is Right**
Midostaurin has been shown to improve overall survival and reduce the risk of relapse in patients with AML, particularly those with FLT3 mutations. This is because the drug effectively inhibits the FLT3 kinase, which is often overexpressed or mutated in AML cells, leading to uncontrolled cell proliferation and resistance to chemotherapy. By targeting FLT3, midostaurin helps to restore normal cell growth and differentiation pathways in AML cells.

**Why Each Wrong Option is Incorrect**
**Option A:** Chronic Myeloid Leukemia (CML) is primarily treated with tyrosine kinase inhibitors like imatinib, which targets the BCR-ABL fusion protein, not the FLT3 kinase.
**Option B:** Acute Lymphoblastic Leukemia (ALL) is typically treated with a combination of chemotherapy and targeted therapies, such as tyrosine kinase inhibitors that target BCR-ABL or other kinases, but not FLT3.
**Option D:** Chronic Lymphocytic Leukemia (CLL) is often treated with chemotherapy, monoclonal antibodies, or targeted therapies that inhibit the B-cell receptor signaling pathway, but not FLT3.

**Clinical Pearl / High-Yield Fact**
Midostaurin is a prime example of a targeted therapy that has improved treatment outcomes for AML patients with FLT3 mutations. It is essential to recognize the specific kinases targeted by this drug and its mechanism of action to make informed treatment decisions.

✓ Correct Answer: C. AML